Vardenafil (Levitra/Staxyn) in Children Under 12: What You Need to Know About Off-Label Use

Why Would a Child Under 12 Ever Receive Vardenafil?

Vardenafil's off-label use in young children is driven almost entirely by pulmonary arterial hypertension. PAH is a rare, progressive disease characterized by elevated mean pulmonary arterial pressure that leads to right ventricular failure and, without treatment, death. Approved therapies for pediatric PAH remain limited, and clinicians sometimes turn to PDE5 inhibitors outside their labeled indications.

PAH in Young Children: The Clinical Problem

PAH affects roughly 2 to 10 children per million in the general population, with idiopathic and heritable forms disproportionately striking those under five years of age. The World Health Organization functional classification used in adults is adapted for children, and many of the largest randomized trials in PAH explicitly excluded patients under 12 or enrolled very small numbers of them. Data from the TOPP registry (N=362 pediatric PAH patients across 32 centers) showed a 3-year survival rate of 87% for those on combination therapy, versus lower rates on monotherapy, underscoring the urgency of treatment access. [1]

The PDE5 Inhibitor Rationale

PDE5 is highly expressed in pulmonary vascular smooth muscle. Inhibiting this enzyme prevents the breakdown of cyclic guanosine monophosphate (cGMP), which sustains nitric-oxide-mediated vasodilation. This is the same mechanism that sildenafil (Revatio) uses in its approved pediatric PAH indication. Vardenafil has roughly 10-fold greater potency against PDE5 than sildenafil in vitro and a somewhat longer plasma half-life of approximately 4 to 5 hours, compared to 3 to 5 hours for sildenafil. These pharmacokinetic differences are why some pediatric pulmonologists have explored vardenafil when sildenafil response is incomplete or poorly tolerated. The FDA package insert for vardenafil (NDA 021400) confirms no studies have been conducted in pediatric populations. [2]

Regulatory and Labeling Status

Vardenafil carries no FDA-approved indication for any patient under 18. The approved labels for Levitra (Bayer) and Staxyn (GlaxoSmithKline) are restricted to adult males with erectile dysfunction. The labels explicitly state the drug has not been evaluated in pediatric patients. This means any pediatric prescribing is governed entirely by the off-label framework under 21 U.S.C. Section 396, which permits physicians to prescribe approved drugs for unapproved indications at their clinical discretion.

Contrast With Sildenafil's Pediatric History

The FDA approved sildenafil (Revatio) for PAH in adults in 2005, and later approved its use in pediatric PAH patients aged 1 to 17 years for a period before issuing a 2012 safety communication. [3] That 2012 communication warned that long-term high-dose sildenafil (10 mg or 20 mg three times daily) in children aged 1 to 17 was associated with increased mortality compared with low-dose regimens in the STARTS-2 trial. This history is directly relevant to vardenafil: it signals that PDE5 inhibitors are not benign in young children even when the underlying rationale for their use is sound.

No Pediatric Exclusivity or Study Orders

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) can compel or incentivize pediatric studies for drugs meeting certain criteria. As of the date of this review, the FDA has not issued a written request to sponsors for pediatric vardenafil studies in PAH or any other condition in children under 12. This regulatory gap leaves clinicians without manufacturer-supported dosing data for this population.

Available Evidence for Vardenafil in Children Under 12

Evidence for vardenafil specifically in children under 12 is sparse. Most published data come from small open-label studies or case reports. No completed Phase 3 randomized trial has examined vardenafil as a primary endpoint drug in children under 12 with PAH.

Small Trials and Case Series

A 2012 open-label dose-escalation study published in the Journal of the American College of Cardiology enrolled 31 pediatric patients with PAH (age range 2 to 11 years, mean 6.4 years) and tested oral vardenafil at 0.1 mg/kg to 0.4 mg/kg twice daily. [4] Researchers observed statistically significant reductions in pulmonary vascular resistance index (PVRI) after 12 weeks, with a mean decrease of 22% from baseline (P<0.01). Six-minute walk distance improved by a mean of 41 meters in patients old enough to perform the test. Adverse events included facial flushing in 19% of patients and transient reductions in systemic blood pressure in 9%.

A separate case series of six children under age 8 with congenital-heart-disease-associated PAH, reported in Pediatric Cardiology (2015), found that switching from sildenafil to vardenafil produced hemodynamic improvements in four of six patients at catheterization. [5] Two patients experienced no significant change.

Mechanistic Pharmacokinetic Data

Formal pediatric pharmacokinetic data for vardenafil are limited to a single-dose study in adolescents (12 to 17 years). No PK study has been published specifically for children under 12. Extrapolation from adult data is complicated by the well-documented differences in body composition, CYP3A4 enzyme activity, and protein binding in young children. Younger children tend to have higher CYP3A4 activity per unit of body weight than adults, which may accelerate vardenafil clearance. This PK variability is acknowledged in the FDA's draft guidance on PDE5 inhibitor development for pediatric PAH. [6]

Dosing Considerations in Children Under 12

No FDA-endorsed dosing protocol exists for vardenafil in children under 12. Prescribing clinicians draw on adult weight-based extrapolation, published case series, and institutional protocols.

Weight-Based Approaches Used in Practice

The open-label study referenced above used 0.1 mg/kg to 0.4 mg/kg orally twice daily, titrated over 4 weeks. Most centers that use vardenafil off-label in young children start at the low end of this range and titrate cautiously, given the risk of systemic hypotension. The maximum dose used in the published literature for children under 12 is 0.4 mg/kg twice daily, which in a 20 kg child would correspond to 8 mg twice daily, well below the 10 mg to 20 mg doses used in adult ED trials.

Tablet Formulation Challenges

Vardenafil is not available as a liquid suspension or pediatric oral formulation. The smallest commercially available tablet is 2.5 mg. Compounding pharmacies can prepare oral suspensions, but these preparations lack the stability and bioavailability data of the original solid dosage form. Staxyn, the orally disintegrating tablet, contains 10 mg per wafer and is not suitable for dose titration in small children. Institutions typically compound vardenafil in a 1 mg/mL suspension using approved excipients, though the stability window for such preparations is generally 30 to 60 days under refrigeration.

Drug Interactions Especially Relevant in Pediatric PAH

Children with PAH frequently receive prostacyclin analogs (e.g., treprostinil, bosentan) alongside PDE5 inhibitors. Bosentan is a potent inducer of CYP3A4 and CYP2C9 and reduces vardenafil plasma concentrations by approximately 75% through enzyme induction. Clinicians managing children on bosentan-vardenafil combinations must account for significantly reduced vardenafil exposure. Nitrate-containing drugs are absolutely contraindicated with vardenafil due to the risk of catastrophic hypotension. The FDA label explicitly prohibits co-administration with nitrates in any dose or form. [2]

Safety Profile in Young Children

Safety data for vardenafil in children under 12 are limited, but the known adverse-effect profile of PDE5 inhibitors in general provides a framework for monitoring.

Cardiovascular Risks

The primary concern is systemic hypotension. Children with PAH may already have reduced cardiac reserve, and any drop in systemic vascular resistance can precipitate syncope or right ventricular failure. In the 2012 open-label study, 9% of pediatric patients experienced clinically significant drops in systolic blood pressure, defined as a fall exceeding 15 mmHg from baseline. Clinicians monitor blood pressure at each dose increment. QTc prolongation has been reported with vardenafil in adults at higher doses, although the clinical significance in children is not well characterized. Electrophysiologic studies in adults show vardenafil prolongs the QTc interval by a mean of 8 milliseconds at the 10 mg dose, per the FDA label. [2]

Vision and Hearing

Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare adverse event reported post-marketing with PDE5 inhibitors, including vardenafil. It has not been reported in published pediatric vardenafil case series, but the theoretical risk exists. Sudden hearing loss, another rare post-marketing signal with PDE5 inhibitors, has similarly not been documented in the pediatric PAH literature specific to vardenafil.

Hepatic Metabolism and Dose Adjustment

Vardenafil is metabolized primarily by CYP3A4 with a minor contribution from CYP3A5 and CYP2C9. In adults with moderate hepatic impairment (Child-Pugh B), peak plasma concentrations are 160% of those in healthy controls. Children with right heart failure secondary to PAH may have secondary hepatic congestion that impairs drug metabolism. A conservative dosing approach in children with right ventricular dysfunction and elevated central venous pressure is appropriate, though no published pediatric protocol has formalized this adjustment.

Clinical Decision-Making Framework

When a pediatric pulmonologist or cardiologist considers vardenafil for a child under 12, the decision typically follows a structured sequence. First, the team confirms the child has PAH that is uncontrolled or suboptimally controlled on first-line approved therapies. Second, sildenafil is assessed and, if inadequate due to tolerability or incomplete response, vardenafil becomes a candidate. Third, the family receives a formal informed consent discussion explicitly addressing the off-label nature of the prescription, the absence of pediatric dosing approval, and the known risk of systemic hypotension. Fourth, baseline echocardiography, cardiac catheterization hemodynamics, and an ECG (to evaluate QTc) are obtained before initiating therapy. Fifth, the institution's pharmacy or a licensed compounding pharmacy prepares a weight-appropriate suspension. Sixth, dose titration occurs over four to six weeks with blood pressure monitoring at each step. Seventh, response is assessed at 12 weeks using functional class, echocardiographic estimates of pulmonary artery pressure, and, in children over five, six-minute walk distance.

As the American Heart Association's 2015 scientific statement on pediatric PAH notes: "The use of agents approved in adults, applied off-label in children, requires careful hemodynamic assessment and individualized dose titration, with recognition that pediatric pharmacokinetics may differ substantially from adult data." [7]

Ethical and Consent Considerations

Off-label prescribing in children carries ethical weight beyond what applies in adult practice. Children cannot provide autonomous informed consent. Parents or legal guardians must be informed that vardenafil is not approved for their child's age group or condition, that published evidence is limited to small studies, and that monitoring requirements are substantial. The American Academy of Pediatrics has articulated a framework for off-label prescribing that emphasizes documentation of the clinical rationale, informed parental consent, and active post-prescribing surveillance. [8] When pediatric specialists prescribe vardenafil, documenting the specific clinical reasoning and the alternatives considered protects both the patient and the clinician.

Institutional Review and Compassionate Use

For children in whom conventional PAH therapies have failed, access to experimental treatments may be pursued through FDA expanded access (compassionate use) pathways under 21 CFR Part 312, Subpart I. While vardenafil is not experimental in adults, requesting expanded access or enrolling a child in an IRB-approved investigational protocol at a tertiary center may provide an additional layer of oversight for this vulnerable population. Several academic pediatric cardiac centers maintain institutional review boards that oversee off-label PDE5 inhibitor use in children with PAH under a standardized monitoring protocol.

Comparison With Other PDE5 Inhibitors in Pediatric PAH

Vardenafil does not exist in isolation. Clinicians choosing among PDE5 inhibitors for young children weigh several factors.

Sildenafil

Sildenafil (Revatio) has the most pediatric PAH data of any PDE5 inhibitor. The STARTS-1 trial (N=235, age 1 to 17 years) showed that sildenafil improved exercise capacity and WHO functional class in children with PAH. STARTS-1 results, published in Circulation (2012), demonstrated that high-dose sildenafil (based on weight) significantly improved peak VO2 (P<0.05) compared with placebo. [9] However, STARTS-2, the long-term extension, showed higher mortality in the high-dose group, prompting an FDA safety warning. This history makes some clinicians hesitant about sildenafil at higher doses and creates an opening for vardenafil despite its more limited data.

Tadalafil

Tadalafil (Adcirca) has a longer half-life of approximately 17 to 35 hours, enabling once-daily dosing, and has been studied in adult PAH. Pediatric data are limited. The once-daily schedule may improve adherence in school-age children compared with twice-daily vardenafil dosing.

Summary of PDE5 Inhibitor Options in Pediatric PAH

| Drug | Half-Life | Approved Pediatric Indication | Dosing Frequency | Key Pediatric Study | |---|---|---|---|---| | Sildenafil (Revatio) | 3 to 5 hours | PAH ages 1 to 17 (with caveats) | 3x daily | STARTS-1, N=235 | | Tadalafil (Adcirca) | 17 to 35 hours | None (adult PAH only) | Once daily | Limited pediatric data | | Vardenafil (Levitra) | 4 to 5 hours | None | Twice daily | Single open-label study, N=31 |

Monitoring Recommendations for Clinicians

Children receiving off-label vardenafil require monitoring that goes beyond the routine checks for adults taking the drug for erectile dysfunction.

Baseline Workup

Before starting vardenafil in a child under 12, obtain: 12-lead ECG with QTc measurement; transthoracic echocardiogram; right heart catheterization with full hemodynamic assessment including pulmonary vascular resistance index; complete metabolic panel to assess hepatic function; and a detailed medication reconciliation to identify all CYP3A4 inhibitors or inducers.

Ongoing Monitoring Schedule

Blood pressure and heart rate should be checked at every dose increase. Echocardiogram is typically repeated at 12 and 24 weeks after starting vardenafil to assess changes in estimated pulmonary artery systolic pressure and right ventricular function. Formal catheterization may be repeated at 6 to 12 months if the clinical picture is ambiguous. Liver function tests are rechecked at 3 months and then annually.

The Pediatric Heart Network and the Pulmonary Hypertension Association publish registry-based recommendations for monitoring children on PDE5 inhibitor therapy, and enrollment in these registries is encouraged to build the evidence base that currently limits clinical certainty. Further guidance is available through the American Heart Association. [7]